Investigational drug · Phase 3
DB-1311
Also called: BNT324
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Metastatic Castration-resistant Prostate Cancer, Advanced Lung Cancer, Solid Tumors.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
4
4 still active
All registered trials
4
Any phase or sponsor naming "DB-1311"
First trial start
2023
Aug 17, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "DB-1311", any sponsor or status.
Conditions studied
As listed on its trial records.
- Metastatic Castration-resistant Prostate Cancer
- Advanced Lung Cancer
- Solid Tumors
- Advanced Solid Tumors
Approved drugs for the same conditions: Prostate cancer · Oncology · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "DB-1311" as an intervention, largest first.
DualityBio Inc.Industry
NCT05914116 · 862 participants (planned) · Start Aug 17, 2023 · Primary completion Dec 2027
Drug: DB-1311; Lopinavir and Ritonavir Tablets and 3 more · For: Advanced Solid Tumors
Sites: Tucson, Arizona; Los Angeles, California; Santa Monica, California · 107 sites in all
- DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid TumorsPivotal-lookingRecruiting
DualityBio Inc.Industry
NCT06953089 · 750 participants (planned) · Start Jul 18, 2025 · Primary completion Jun 30, 2030
Drug: DB-1311/BNT324; BNT327 and 1 more · For: Solid Tumors
Sites: Los Angeles, California; Wheat Ridge, Colorado; Florida City, Florida · 37 sites in all
- A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate CancerPivotal-lookingRecruiting
BioNTech SEIndustry
NCT07365995 · 736 participants (planned) · Start Apr 22, 2026 · Primary completion Feb 2031
Drug: BNT324; Docetaxel and 1 more · For: Metastatic Castration-resistant Prostate Cancer
Sites: Tucson, Arizona; Santa Barbara, California; Aurora, Colorado · 77 sites in all
- A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung CancerPivotal-lookingRecruiting
BioNTech SEIndustry
NCT06892548 · 594 participants (planned) · Start May 2, 2025 · Primary completion Sep 2028
Drug: BNT324; BNT327 · For: Advanced Lung Cancer
Sites: Phoenix, Arizona; Beverly Hills, California; Los Angeles, California · 91 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- [Recent advances in antibody-drug conjugates for metastatic castration-resistant prostate cancer].
Xu J, Ma Y, Hu P, et al. · Zhejiang Da Xue Xue Bao Yi Xue Ban 2025
Also in development for Metastatic Castration-resistant Prostate Cancer
- VolrustomigMEDI5752Phase 313 trials
AstraZeneca · Gastric Cancer, Non-small Cell Lung Cancer, Biliary Tract Cancer
- OpevesostatMK-5684, ODM-208Phase 37 trials
Merck & Co. · Prostate Cancer Metastatic, Malignant Neoplasm, Metastatic Castration-resistant Prostate Cancer (mCRPC)
- ONC-392Gotistobart, BNT316Phase 35 trials
OncoC4, Inc. · Non Small Cell Lung Cancer, Ovarian Cancer, Advanced Solid Tumor
- MevrometostatPF-06821497Phase 33 trials
Pfizer · Metastatic Castration Sensitive Prostate Cancer (mCSPC), Hormone Sensitive Prostate Cancer, Prostate Cancer
- 177Lu-NYM032Phase 32 trials
Norroy Bioscience Co., LTD · Prostate Cancer, Metastatic Castration-resistant Prostate Cancer
- XaluritamigAMG 509Phase 32 trials
Amgen · Metastatic Castration-resistant Prostate Cancer
- BMS-986365Phase 31 trial
Bristol Myers Squibb · Metastatic Castration-resistant Prostate Cancer
- DeutenzalutamidePhase 31 trial
AstraZeneca · Metastatic Castration-resistant Prostate Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.